Global Biologics CDMO 麻豆原创 Growth 2025-2031

Publication ID:

LPI03258430

Publication Date:

March 28, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Biologics CDMO market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Biologics CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Biologics CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Biologics CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Biologics CDMO players cover Lonza Group AG, Samsung Biologics, AbbVie, WuXi Biologics, Toyobo, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淏iologics CDMO Industry Forecast鈥� looks at past sales and reviews total world Biologics CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Biologics CDMO sales for 2025 through 2031. With Biologics CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics CDMO industry.
This Insight Report provides a comprehensive analysis of the global Biologics CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biologics CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Biologics CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics CDMO market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Biological Agent
Biosimilar Drug
Segmentation by Application:
Cell Therapy
Drug Development
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Lonza Group AG
Samsung Biologics
AbbVie
WuXi Biologics
Toyobo
AGC
Thermo Fisher Scientific
ICON Plc
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
Key Questions Addressed in this Report
What is the 10-year outlook for the global Biologics CDMO market?
What factors are driving Biologics CDMO market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Biologics CDMO market opportunities vary by end market size?
How does Biologics CDMO break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Biologics CDMO Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Biologics CDMO by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Biologics CDMO by Country/Region, 2020, 2024 & 2031
2.2 Biologics CDMO Segment by Type
2.2.1 Biological Agent
2.2.2 Biosimilar Drug
2.3 Biologics CDMO Sales by Type
2.3.1 Global Biologics CDMO Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Biologics CDMO Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Biologics CDMO Sale Price by Type (2020-2025)
2.4 Biologics CDMO Segment by Application
2.4.1 Cell Therapy
2.4.2 Drug Development
2.4.3 Others
2.5 Biologics CDMO Sales by Application
2.5.1 Global Biologics CDMO Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Biologics CDMO Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Biologics CDMO Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Biologics CDMO Breakdown Data by Company
3.1.1 Global Biologics CDMO Annual Sales by Company (2020-2025)
3.1.2 Global Biologics CDMO Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Biologics CDMO Annual Revenue by Company (2020-2025)
3.2.1 Global Biologics CDMO Revenue by Company (2020-2025)
3.2.2 Global Biologics CDMO Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Biologics CDMO Sale Price by Company
3.4 Key Manufacturers Biologics CDMO Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biologics CDMO Product Location Distribution
3.4.2 Players Biologics CDMO Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Biologics CDMO by Geographic Region
4.1 World Historic Biologics CDMO 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Biologics CDMO Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Biologics CDMO Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Biologics CDMO 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Biologics CDMO Annual Sales by Country/Region (2020-2025)
4.2.2 Global Biologics CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Biologics CDMO Sales Growth
4.4 APAC Biologics CDMO Sales Growth
4.5 Europe Biologics CDMO Sales Growth
4.6 Middle East & Africa Biologics CDMO Sales Growth
5 Americas
5.1 Americas Biologics CDMO Sales by Country
5.1.1 Americas Biologics CDMO Sales by Country (2020-2025)
5.1.2 Americas Biologics CDMO Revenue by Country (2020-2025)
5.2 Americas Biologics CDMO Sales by Type (2020-2025)
5.3 Americas Biologics CDMO Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologics CDMO Sales by Region
6.1.1 APAC Biologics CDMO Sales by Region (2020-2025)
6.1.2 APAC Biologics CDMO Revenue by Region (2020-2025)
6.2 APAC Biologics CDMO Sales by Type (2020-2025)
6.3 APAC Biologics CDMO Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Biologics CDMO by Country
7.1.1 Europe Biologics CDMO Sales by Country (2020-2025)
7.1.2 Europe Biologics CDMO Revenue by Country (2020-2025)
7.2 Europe Biologics CDMO Sales by Type (2020-2025)
7.3 Europe Biologics CDMO Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biologics CDMO by Country
8.1.1 Middle East & Africa Biologics CDMO Sales by Country (2020-2025)
8.1.2 Middle East & Africa Biologics CDMO Revenue by Country (2020-2025)
8.2 Middle East & Africa Biologics CDMO Sales by Type (2020-2025)
8.3 Middle East & Africa Biologics CDMO Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biologics CDMO
10.3 Manufacturing Process Analysis of Biologics CDMO
10.4 Industry Chain Structure of Biologics CDMO
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Biologics CDMO Distributors
11.3 Biologics CDMO Customer
12 World Forecast Review for Biologics CDMO by Geographic Region
12.1 Global Biologics CDMO 麻豆原创 Size Forecast by Region
12.1.1 Global Biologics CDMO Forecast by Region (2026-2031)
12.1.2 Global Biologics CDMO Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Biologics CDMO Forecast by Type (2026-2031)
12.7 Global Biologics CDMO Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Lonza Group AG
13.1.1 Lonza Group AG Company Information
13.1.2 Lonza Group AG Biologics CDMO Product Portfolios and Specifications
13.1.3 Lonza Group AG Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Lonza Group AG Main Business Overview
13.1.5 Lonza Group AG Latest Developments
13.2 Samsung Biologics
13.2.1 Samsung Biologics Company Information
13.2.2 Samsung Biologics Biologics CDMO Product Portfolios and Specifications
13.2.3 Samsung Biologics Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Samsung Biologics Main Business Overview
13.2.5 Samsung Biologics Latest Developments
13.3 AbbVie
13.3.1 AbbVie Company Information
13.3.2 AbbVie Biologics CDMO Product Portfolios and Specifications
13.3.3 AbbVie Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AbbVie Main Business Overview
13.3.5 AbbVie Latest Developments
13.4 WuXi Biologics
13.4.1 WuXi Biologics Company Information
13.4.2 WuXi Biologics Biologics CDMO Product Portfolios and Specifications
13.4.3 WuXi Biologics Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 WuXi Biologics Main Business Overview
13.4.5 WuXi Biologics Latest Developments
13.5 Toyobo
13.5.1 Toyobo Company Information
13.5.2 Toyobo Biologics CDMO Product Portfolios and Specifications
13.5.3 Toyobo Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Toyobo Main Business Overview
13.5.5 Toyobo Latest Developments
13.6 AGC
13.6.1 AGC Company Information
13.6.2 AGC Biologics CDMO Product Portfolios and Specifications
13.6.3 AGC Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 AGC Main Business Overview
13.6.5 AGC Latest Developments
13.7 Thermo Fisher Scientific
13.7.1 Thermo Fisher Scientific Company Information
13.7.2 Thermo Fisher Scientific Biologics CDMO Product Portfolios and Specifications
13.7.3 Thermo Fisher Scientific Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Thermo Fisher Scientific Main Business Overview
13.7.5 Thermo Fisher Scientific Latest Developments
13.8 ICON Plc
13.8.1 ICON Plc Company Information
13.8.2 ICON Plc Biologics CDMO Product Portfolios and Specifications
13.8.3 ICON Plc Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 ICON Plc Main Business Overview
13.8.5 ICON Plc Latest Developments
13.9 Boehringer Ingelheim
13.9.1 Boehringer Ingelheim Company Information
13.9.2 Boehringer Ingelheim Biologics CDMO Product Portfolios and Specifications
13.9.3 Boehringer Ingelheim Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Boehringer Ingelheim Main Business Overview
13.9.5 Boehringer Ingelheim Latest Developments
13.10 Fujifilm Diosynth Biotechnologies
13.10.1 Fujifilm Diosynth Biotechnologies Company Information
13.10.2 Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolios and Specifications
13.10.3 Fujifilm Diosynth Biotechnologies Biologics CDMO Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Fujifilm Diosynth Biotechnologies Main Business Overview
13.10.5 Fujifilm Diosynth Biotechnologies Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.